Evidence map›Paper›PMID 28792540›Full record

ArticlePloS one2017

Antibiotics resistance in El Tor Vibrio cholerae 01 isolated during cholera outbreaks in Mozambique from 2012 to 2015.

Liliana Candida Dengo-Baloi, Cynthia Amino Semá-Baltazar, Lena Vania Manhique, Jucunu Elias Chitio, Dorteia Luísa Inguane, José Paulo Langa

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed, 5 pooled it
5.6field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 5 syntheses or guidelines pooled it, 71 citations in OpenAlex.

  1. Antimicrobial Resistance of EnvironmentalInfectious disorders drug targets · 2025
    Pooled it
  2. Pooled it
  3. Antimicrobial resistance among clinicalPathogens and global health · 2023
    Pooled it
  4. Pooled it
  5. Pooled it
  6. Article
  7. Article
  8. Article
  9. Genomic portrayal of emerging carbapenem-resistant El Tor variantAntimicrobial agents and chemotherapy · 2025
    Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Anti-Cholera toxin activity of selected polyphenols fromFrontiers in cellular and infection microbiology · 2023
    Article
  15. Resistance ofFrontiers in pharmacology · 2023
    Review
  16. Article
  17. Review
  18. Review
  19. Article
  20. Assessment and Antibiotic Resistance Profiling inAntibiotics (Basel, Switzerland) · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Liliana Candida Dengo-BaloiInstituto Nacional de Saúde, Maputo, Moçambique.ORCID http://orcid.org/0000-0002-0504-6599
Cynthia Amino Semá-BaltazarInstituto Nacional de Saúde, Maputo, Moçambique.
Lena Vania ManhiqueInstituto Nacional de Saúde, Maputo, Moçambique.
Jucunu Elias ChitioInstituto Nacional de Saúde, Maputo, Moçambique.
Dorteia Luísa InguaneInstituto Nacional de Saúde, Maputo, Moçambique.
José Paulo LangaInstituto Nacional de Saúde, Maputo, Moçambique.
Instituto Nacional de Saúde · MZ

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

rationaleMozambique has recorded cyclically epidemic outbreaks of cholera. Antibiotic therapy is recommended in specific situations for management and control of cholera outbreaks. However, an increase in resistance rates to antibiotics by Vibrio cholerae has been reported in several epidemic outbreaks worldwide. On the other hand, there are few recent records of continuous surveillance of antibiotics susceptibility pattern of V. cholerae in Mozambique. GOALS: The purpose of this study was to evaluate antibiotics resistance pattern of Vibrio cholerae O1 Ogawa isolated during Cholera outbreaks in Mozambique to commonly used antibiotics. METHODOLOGY: We analyzed data from samples received in the context of surveillance and response to Cholera outbreaks in the National Reference Laboratory of Microbiology from the National Institute of Health of Mozambique, 159 samples suspected of cholera from cholera treatment centers of, Metangula (09), Memba (01), Tete City (08), Moatize (01), Morrumbala (01) districts, City of Quelimane (01), Lichinga (06) and Nampula (86) districts, from 2012 to 2015. Laboratory culture and standard biochemical tests were employed to isolate and identify Vibrio cholerae; serotypes were determined by antisera agglutination reaction in blade. Biotype and presence of important virulence factors analysis was done by PCR. Antibiotics susceptibility pattern was detected by disk diffusion method Kirby Bauer. Antibiotic susceptibility and results were interpreted by following as per recommendations of CLSI (Clinical and Laboratory Standards Institute) 2014. All samples were collected and tested in the context of Africhol Project, approved by the National Bioethics Committee for Health.

resultsAmong isolates from of Vibrio cholerae O1 El Tor Ogawa resistance to Sulphamethoxazole-trimethropim was 100% (53/53) to Trimethoprim-, being 100% (54/54) for Ampicillin, 99% (72/74) for Nalidixic Acid, 97% (64/66) to Chloramphenicol, 95% (42/44) for Nitrofurantoin and (19/20) Cotrimoxazole, 83% (80/97) Tetracycline, 56% (5/13) Doxycycline, 56% (39/70) Azithromycin and 0% (0/101) for Ciprofloxacin. PCR analysis suggested strains of V. cholerae O1 being descendants of the current seventh pandemic V. cholerae O1 CIRS 101 hybrid variant. The V. cholerae O1 currently causing cholera epidemics in north and central Mozambique confirmed a CTXΦ genotype and a molecular arrangement similar to the V. cholerae O1 CIRS 101.

conclusionAlthough V. cholerae infections in Mozambique are generally not treated with antibiotics circulating strains of the bacteria showed high frequency of in vitro resistance to available antibiotics. Continuous monitoring of antibiotic resistance pattern of epidemic strains is therefore crucial since the appearance of antibiotic resistance can influence cholera control strategies.

Indexed as

Drug Resistance, BacterialAnti-Bacterial AgentsCholeraCluster AnalysisDisease OutbreaksHumansMicrobial Sensitivity TestsMozambiquePolymerase Chain ReactionVibrio cholerae O1Anti-Bacterial Agents

Identifiers

PMID28792540
PMCPMC5549693
OpenAlexW2743191501

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.